All lobbying filings

SPLITOAK STRATEGIES LLC

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 2

HR 1672
Maintaining Investments in New Innovation Act
HR 946
ORPHAN Cures Act

Lobbying activity 1

Medicare/Medicaid

RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946, ORPHAN Cures Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.